Oral Brain Natriuretic Peptide: A Novel Strategy for Chronic Protein Therapy for Cardiovascular Disease

Trends in Cardiovascular Medicine

Volumn 17, Issue 1, 2007, Pages 10-14

  Cataliotti, Alessandro ^a   Chen, Horng H ^a   James, Kenneth D ^a   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE 021; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; ENZYME DEGRADATION; HEART FAILURE; HUMAN; HYPERTENSION; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; TREATMENT OUTCOME; VASODILATATION;

ADMINISTRATION, ORAL; AMINO ACID SEQUENCE; CARDIOVASCULAR DISEASES; HUMANS; MOLECULAR SEQUENCE DATA; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN;

EID: 33845929475     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2006.10.001     Document Type: Review

References (27)

1. Abuchowski A., McCoy J., Palczuk N., et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252 (1977) 3582-3586
2. Abuchowski A., Van Es T., Palczuk N., and Davis F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252 (1977) 3578-3581
3. Belluardo P., Cataliotti A., Bonaiuto L., et al. Lack of activation of the molecular forms of the Bnp system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol 291 (2006) H1529-H1535
4. Brandt I., Lambeir A., Ketelslegers J., et al. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 52 (2006) 82-87
5. Cataliotti A., Boerrigter G., Costello-Boerrigter L., et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 109 (2004) 1680-1685
6. Cataliotti A., Schirger J., Martin F., et al. Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation 112 (2005) 836-840
7. Chen H., Grantham J., Schirger J., et al. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 36 (2000) 1706-1712
8. Chen H., Redfield M., Nordstrom L., et al. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail 10 (2004) 115-119
9. De Bold A., Borenstein H., Veress A., and Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28 (1981) 89-94
10. D'Souza S., Yellon D., Martin C., et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 284 (2003) H1592-H1600
11. Garbers D., Chrisman T., Wiegn P., et al. Membrane guanylyl cyclase receptors: an update. Trends Endocrinol Metab 17 (2006) 251-258
12. Holtwick R., Van Eickels M., Skryabin B., et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 111 (2003) 1399-1407
13. Hooper J., Scarman A., Clarke B., et al. Localization of the mosaic transmembrane serine protease corin to heart myocytes. Eur J Biochem 267 (2000) 6931-6937
14. Kangawa K., Fukuda A., Kubota I., et al. Human atrial natriuretic polypeptides (hANP): purification, structure synthesis and biological activity. J Hypertens Suppl 2 (1984) S321-S323
15. Kapoun A., Liang F., O'Young G., et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 94 (2004) 453-461
16. Kisch B. Electron microscopy of the atrium of the heart. I. Guinea pig. Exp Med Surg 14 (1956) 99-112
17. Leeson P., and Davis A. Time-related differences in the physical property profiles of oral drugs. J Med Chem 47 (2004) 6338-6348
18. Miller M., Malkar N., Severynse-Stevens D., et al. Amphiphilic conjugates of human brain natriuretic peptide designed for oral delivery: in vitro activity screening. Bioconjugate. Chem 17 (2006) 267-274
19. Patel J., Valencik M., Pritchett A., et al. Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 289 (2005) H777-H784
20. Silver M., Maisel A., Yancy C., et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 10 (2004) 1-30
21. Sudoh T., Kangawa K., Minamino N., and Matsuo H. A new natriuretic peptide in porcine brain. Nature 332 (1988) 78-81
22. Tsujita Y., Muraski J., Shiraishi I., et al. Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A 103 (2006) 11946-11951
23. Tsuruda T., Boerrigter G., Huntley B., et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91 (2002) 1127-1134
24. Veronese F. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22 (2001) 405-417
25. Yamahara K., Itoh H., Chun T., et al. Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci U S A 100 (2003) 3404-3409
26. Yan W., Sheng N., Seto M., et al. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J Biol Chem 274 (1999) 14926-14935
27. Yan W., Wu F., Morser J., and Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A 97 (2000) 8525-8529